Compare HUBCW & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUBCW | SRPT |
|---|---|---|
| Founded | N/A | 1980 |
| Country | Israel | United States |
| Employees | 322 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.5B |
| IPO Year | N/A | 2000 |
| Metric | HUBCW | SRPT |
|---|---|---|
| Price | $0.01 | $17.56 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 29 |
| Target Price | N/A | ★ $25.85 |
| AVG Volume (30 Days) | 155.7K | ★ 2.6M |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.49 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $0.00 | $10.42 |
| 52 Week High | $0.04 | $44.14 |
| Indicator | HUBCW | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 50.92 | 33.38 |
| Support Level | $0.01 | $17.11 |
| Resistance Level | $0.03 | $19.62 |
| Average True Range (ATR) | 0.00 | 1.10 |
| MACD | 0.00 | -0.44 |
| Stochastic Oscillator | 14.93 | 0.00 |
Hub Cyber Security Ltd is engaged in the development of cyber products, software, quality systems, reliability, and risk management. It operates in several countries and provides cybersecurity computing appliances as well as a wide range of cybersecurity professional services. The company has two operating segments: the Product and Technology Segment, and the Professional Services Segment. The majority of its revenue comes from the professional services segment, which provides data and cybersecurity, system security and reliability solutions, as well as related services such as consulting, planning, training, integration, and ongoing servicing of cybersecurity, risk management, system quality, reliability, and security projects, including fully managed corporate cybersecurity services.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.